advertisement
Abstract #15220 Published in IGR 8-4
Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension
Cantor LB; Hoop J; Morgan L; WuDunn D; Catoira Y; Bimatoprost-Travoprost Study GroupBritish Journal of Ophthalmology 2006; 90: 1370-1373
AIM: To evaluate the efficacies of bimatoprost and travoprost for lowering of intraocular pressure (IOP) for the treatment of glaucoma and ocular hypertension. METHODS: Prospective, randomised, investigator-blinded, parallel-group clinical trial. After completing a washout of all glaucoma drugs, patients (n = 157) were randomised to bimatoprost or travoprost for 6 months. Visits were at baseline, 1 week, and 1, 3 and 6 months. IOP was measured at 09:00 h at each visit and also at 13:00 and 16:00 h at baseline and at 3 and 6 months. RESULTS: No significant between-group differences were observed in IOP at baseline, at 09:00, 13:00 or 16:00 h (p ≥ 0.741). After 6 months, both drugs significantly reduced IOP at every time point (p ≤ 0.001). After 6 months, mean IOP reduction at 09:00 h was 7.1 mmHg (27.9%) with bimatoprost (n = 76) and 5.7 mmHg (23.3%) with travoprost (n = 81; p = 0.014). At 13:00 h, mean IOP reduction was 5.9 mmHg with bimatoprost (25.3%) and 5.2 mmHg (22.4%) with travoprost (p = 0.213). At 16:00 h, the mean IOP reduction was 5.3 mmHg (22.5%) with bimatoprost and 4.5 mmHg (18.9%; p = 0.207) with travoprost. Both study drugs were well tolerated, with ocular redness the most commonly reported adverse event in both treatment groups. CONCLUSIONS: Bimatoprost provided greater mean IOP reductions than travoprost.
Dr. L.B. Cantor, Department of Ophthalmology, Indiana University Medical Center, 702 Rotary Circle, Indianapolis, IN 46202, USA. lcantor@iupui.edu
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
